Regeneron stock: Q3 growth broadens Sanofi alliance
Published on 11/06/2026 at 17:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEarnings, Alliance And Pipeline
- Third-quarter revenue rose 36 percent year over year, while non-GAAP diluted earnings per share increased 70 percent.
- Regeneron and Sanofi expanded their alliance to four next-generation, long-acting antibodies.
- A USD 1.0 billion upfront payment is expected to enter fourth-quarter collaboration revenue.
Regeneron Pharmaceuticals reported strong third-quarter results on Friday, October 30, 2026, and expanded its Sanofi alliance. The company release said revenue for the period ended September 30 increased 36 percent year over year to USD 5.116 billion.
Strong Quarter, Broader Collaboration
GAAP net income rose 33 percent to USD 1.949 billion and diluted GAAP earnings per share increased 35 percent to USD 18.45. Adjusted net income climbed 67 percent to USD 2.150 billion, lifting non-GAAP diluted earnings per share 70 percent to USD 20.07.
Sanofi collaboration revenue reached USD 2.724 billion, up 68 percent year over year. Regeneron said the increase reflected a larger share of antibody commercialization profits, helped by higher Dupixent sales and the repayment of Sanofi's development balance at the end of the second quarter.
The amended alliance adds four Regeneron-invented, next-generation, long-acting antibodies. Regeneron received a USD 1.0 billion upfront payment that it expects to recognize as collaboration revenue in the fourth quarter, with up to an additional USD 7.0 billion tied to development, regulatory and sales milestones.
Pipeline And Investor Watchpoints
Regeneron said its clinical pipeline includes approximately 50 product candidates. The company also reported strong product momentum in the quarter, including EYLEA HD sales of USD 1.083 billion and Libtayo sales of USD 550 million, while combined EYLEA and EYLEA HD sales declined 11 percent as patients continued moving to the newer formulation.
Regeneron stock traded at EUR 808.30 on Lang & Schwarz at 17:12 CET on Friday, November 6, 2026. That was 8.77 percent below the EUR 885.95 quote in the latest relevant report published on November 4 at 14:41 CET, a separate comparison from any Xetra session. Investors can follow the real-time quote of Regeneron stock.
Regeneron Pharmaceuticals
- ISIN: US75886F1075
- Ticker: REGN
- Home exchange: Nasdaq
- Latest quote: EUR 808.30 on Lang & Schwarz, November 6, 2026 at 17:12 CET
- Change since latest report: 8.77 percent lower than EUR 885.95 on November 4, 2026
- Reporting period: Third quarter 2026 ended September 30
- Revenue: USD 5.116 billion, up 36 percent year over year
- Non-GAAP diluted earnings per share: USD 20.07, up 70 percent year over year
US equities provide the relevant market backdrop for Regeneron through the S&P 500.
More news and analyses on Regeneron stock cover the company's pipeline, products and collaboration milestones.
